🇺🇸 FDA
Patent

US 7612044

Melanoma antigens and their use in diagnostic and therapeutic methods

granted A61KA61K2039/5256A61K2039/53

Quick answer

US patent 7612044 (Melanoma antigens and their use in diagnostic and therapeutic methods) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Oct 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Nov 03 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/5256, A61K2039/53, A61K2239/31, A61K2239/38